---
title: "ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291275727.md"
description: "ADC Therapeutics SA, based in Lausanne, Switzerland, recently announced the treatment of 100 patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) using a selected dose of 150 µg/kg of ZYNLONTA® combined with glofitamab. The full data from this treatment is anticipated to be revealed in the fourth quarter of 2026. The company, known as a pioneer in this field, is listed on the NYSE under the ticker ADCT."
datetime: "2026-06-30T11:17:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291275727.md)
  - [en](https://longbridge.com/en/news/291275727.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291275727.md)
---

# ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA® Combination Trial

ADC Therapeutics SA, based in Lausanne, Switzerland, recently announced the treatment of 100 patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) using a selected dose of 150 µg/kg of ZYNLONTA® combined with glofitamab. The full data from this treatment is anticipated to be revealed in the fourth quarter of 2026. The company, known as a pioneer in this field, is listed on the NYSE under the ticker ADCT.

### Related Stocks

- [ADCT.US](https://longbridge.com/en/quote/ADCT.US.md)

## Related News & Research

- [ADC Therapeutics completes LOTIS-7 Phase 1b enrollment for Zynlonta-glofitamab combo in r/r DLBCL](https://longbridge.com/en/news/291272696.md)
- [ADC Therapeutics reports positive LOTIS-5 PFS results; plans pre-sBLA meeting and Q4 2026 sBLA](https://longbridge.com/en/news/288624565.md)
- [Analyst Backs Crescent Biopharma With Buy Rating on Advancing ADC Pipeline and Strong Cash Runway](https://longbridge.com/en/news/294417283.md)
- [Adlai Nortye Initiated With Buy on Differentiated RAS-Targeting Pipeline, ADC Strategy and Solid Cash Runway](https://longbridge.com/en/news/293951548.md)
- [Chemed Q2 revenue beats estimates, helped by VITAS segment growth](https://longbridge.com/en/news/294109919.md)